Dose Table

Sialanar® is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders.1 Adverse event reporting information can be found at the bottom of the page.

Dose table for children and adolescents with normal renal function (glycopyrronium bromide)1

Click on the patient's weight below to find the recommended dose

13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg

13-17 kg

  • Dose Level 1
    ~16 mcg/kg

    0ml*

  • Dose Level 2
    ~32 mcg/kg

    0ml*

  • Dose Level 3
    ~48 mcg/kg

    0ml*

  • Dose Level 4
    ~64 mcg/kg

    0ml*

  • Dose Level 5
    ~80 mcg/kg

    0ml*

* Maximum individual dose in this weight range.

Dose table for children and adolescents with mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2) (glycopyrronium bromide)1

Click on the patient's weight below to find the recommended dose

13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg

13-17 kg

  • Dose Level 1
    ~11 mcg/kg

    0ml*

  • Dose Level 2
    ~22 mcg/kg

    0ml*

  • Dose Level 3
    ~34 mcg/kg

    0ml*

  • Dose Level 4
    ~45 mcg/kg

    0ml*

  • Dose Level 5
    ~56 mcg/kg

    0ml*

* Maximum individual dose in this weight range.

 

Please refer to the SmPC for full dosing information

Request a printed dosing wheel

Submit this form to request a printed dosing wheel to support you or your team:

References

  1. Sialanar® SmPC (January 2023) https://www.medicines.org.uk/emc/product/2301 – accessed December 2024
  2. Parr J.R, Todhunter E, Pennington L, et al. (2017) Drooling Reduction Intervention randomized trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2017; 1-6. Doi:10. 1136/ archdischild-2017-313763.
  3. Reid S.M, et al. (2019) Anticholinergic medications for reducing drooling in children with developmental disability. Developmental Medicine & Child Neurology; 63(3): 346-353

UK-SIA-24-0056 | December 2024

Please see below for information on how to report an adverse event in the UK or Republic of Ireland:

UK
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Proveca Limited. Phone: 0333 200 1866 E-Mail: medinfo@proveca.com

Republic of Ireland
Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

You are now leaving a Proveca website.

Proveca are not responsible for the content on this website.

Continue